ST Pharm Co.,Ltd. (237690.KQ) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	386.3B	331.6B	273.8B	285.0B	249.3B
Cost of Revenue	236.5B	202.4B	177.6B	178.4B	166.0B
Gross Profit	149.9B	129.3B	96.2B	106.6B	83.3B
Operating Expenses
R&D Expense	24.4B	21.0B	22.1B	30.4B	26.3B
SG&A Expense	22.5B	12.6B	11.1B	9.8B	40.3B
General & Admin Expense	5.6B	7.0B	6.0B	5.0B	6.0B
Selling & Marketing Expense	4.2B	5.6B	5.1B	4.8B	3.2B
Other Expenses	38.0B	41.2B	35.3B	35.4B	(1.2B)
Total Operating Expenses	79.4B	74.8B	68.5B	75.6B	65.4B
Cost and Expenses	315.6B	276.5B	246.1B	254.0B	231.5B
Operating Income (EBIT)	70.6B	54.5B	27.7B	31.0B	17.9B
Non-Operating
Interest Income	25.0B	3.5B	4.6B	2.4B	1.2B
Interest Expense	9.6B	4.0B	7.7B	6.1B	2.9B
Net Interest Income	15.4B	(583.2M)	(3.2B)	(3.7B)	(1.6B)
Other Non-Op Income/Expense	15.4B	4.2B	15.1B	(7.7B)	1.4B
Non-Operating Income (excl Interest)	—	(7.8B)	(22.8B)	1.6B	(4.3B)
EBT (Pre-Tax Income)	86.1B	58.9B	42.7B	23.4B	19.2B
Income Tax Expense	9.2B	4.2B	10.3B	5.8B	1.7B
Bottom Line
Net Income	76.8B	55.0B	34.7B	19.6B	18.0B
Earnings from Cont. Ops	76.8B	54.5B	32.5B	17.5B	17.5B
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	76.8B	57.7B	34.7B	19.6B	18.0B
Per Share
Basic EPS	₩3,696	₩2,706	₩1,780	₩1,041	₩957
Diluted EPS	₩3,694	₩2,688	₩1,780	₩1,041	₩957
Revenue Per Share	₩18,591	₩16,125	₩14,036	₩15,152	₩13,255
Shares
Basic Shares Outstanding	20.8M	20.6M	19.5M	18.8M	18.8M
Diluted Shares Outstanding	20.8M	20.6M	19.5M	18.8M	18.8M
Profitability Metrics
EBITDA	104.3B	84.4B	76.1B	52.5B	39.7B
D&A	33.8B	29.9B	25.6B	23.0B	17.6B
EBIT	70.6B	54.5B	50.5B	29.5B	22.1B

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026